Hyperion DeFi, Inc. (NASDAQ:HYPD) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Hyperion DeFi, Inc. (NASDAQ:HYPD) have earned an average rating of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $4.5833.

HYPD has been the topic of several recent analyst reports. Chardan Capital set a $7.75 price target on shares of Hyperion DeFi and gave the company a “buy” rating in a research note on Wednesday, December 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Hyperion DeFi to a “hold” rating in a report on Monday, December 29th. Cantor Fitzgerald initiated coverage on shares of Hyperion DeFi in a research report on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Hyperion DeFi from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd.

Hyperion DeFi Trading Up 5.0%

HYPD opened at $3.57 on Monday. Hyperion DeFi has a one year low of $0.85 and a one year high of $17.18. The company has a market cap of $29.17 million, a P/E ratio of -0.88 and a beta of 2.74. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. The business’s 50-day simple moving average is $3.46 and its 200-day simple moving average is $5.47.

Insider Transactions at Hyperion DeFi

In other news, Director Happy David Walters bought 61,930 shares of Hyperion DeFi stock in a transaction dated Wednesday, December 17th. The stock was acquired at an average cost of $3.02 per share, with a total value of $187,028.60. Following the acquisition, the director owned 111,930 shares of the company’s stock, valued at approximately $338,028.60. This trade represents a 123.86% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO David R. Knox bought 27,950 shares of the firm’s stock in a transaction that occurred on Wednesday, December 31st. The stock was purchased at an average cost of $3.59 per share, with a total value of $100,340.50. Following the completion of the transaction, the chief financial officer owned 327,950 shares in the company, valued at approximately $1,177,340.50. This trade represents a 9.32% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 189,204 shares of company stock worth $611,467. 10.86% of the stock is owned by company insiders.

Institutional Investors Weigh In On Hyperion DeFi

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HYPD. Jane Street Group LLC purchased a new position in shares of Hyperion DeFi during the fourth quarter worth approximately $493,000. Renaissance Technologies LLC purchased a new stake in Hyperion DeFi in the 4th quarter valued at $663,000. Focus Partners Advisor Solutions LLC purchased a new stake in Hyperion DeFi in the 4th quarter valued at $221,000. Geode Capital Management LLC acquired a new stake in Hyperion DeFi during the 4th quarter worth $214,000. Finally, State Street Corp acquired a new stake in Hyperion DeFi during the 4th quarter worth $92,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.